Celcuity completes enrollment for PIK3CA mutant cohort in phase 3 trial
PositiveFinancial Markets

Celcuity has successfully completed enrollment for its PIK3CA mutant cohort in a phase 3 clinical trial, marking a significant milestone in cancer research. This trial aims to evaluate the effectiveness of a new treatment for patients with specific mutations, which could lead to improved outcomes and options for those affected by this type of cancer. The completion of enrollment is a crucial step towards potentially bringing innovative therapies to market.
— Curated by the World Pulse Now AI Editorial System